of C-circles significantly correlated with IDH1/2 mutation, MGMT exon 1 methylation, low Ki-67 immunostaining, increased telomeric DNA content, absence of functional ATRX protein and level of HTERT gene expression. In multivariate analysis, we observed a trend to a correlation between elevated TERRA levels and increased survival. Interestingly, the C-circles assay allowed to detect ALT activation in glioblastomas exhibiting wild-type IDH1/2 and ATRX expression. These results suggest that, after the correlations uncovered here have been confirmed on larger numbers of tumors, telomeric markers might be useful in improving diagnosis. They also point out to the utility of using the specific, sensitive and quantitative C-circle and Telo/Alu assays that can work with as few as 30 ng of tumor DNA.
Introduction
Telomeres, which represent the ends of linear chromosomes of eukaryotic organisms and contain repeated noncoding TG-rich sequences, protect chromosome ends from DNA repair activities occurring following DNA damage. By limiting the replicative potential of cells, telomere length serves as a "mitotic clock" and telomere erosion acts as a barrier against tumorigenesis in healthy tissue [1] . Following cancer initiation, tumor cells must overcome the telomere-controlled replicative senescence barrier to be able to proliferate indefinitely. In most cases (around 90% of cancer types) this occurs through up-regulation of telomerase expression. However, some cancer cells maintain their telomeres through a telomerase-independent process termed ALT, for "alternative lengthening of telomeres" [2] . ALT is thought to function principally by exchange of telomeric sequences from one telomere to the next (recombination). There is also good evidence that a sort of "rolling circle" mechanism could also lead to telomere amplification on a single telomere [3, 4] . Human gliomas are among the ~10% of cancer types that can survive either owing to telomerase or the ALT pathway [5] . Clinical studies indicate that 15-45% of human malignant gliomas develop the ALT pathway and that this is strongly associated with the low grade II which can exhibit up to 75% of ALT [6, 7] .
Recent clinical studies have highlighted the existence of a strong correlation between the occurrence of the ALT pathway of telomere maintenance in several types of ALT cancers and the presence of mutations in the ATRX ("Alpha Thalassemia/mental Retardation syndrome X-linked") gene [8] . ATRX is a DNA helicase/ATPase of the SWI2/SNF2 family that binds repeated sequences of DNA, particularly the G-rich ones, and has been implicated mainly in chromatin remodeling [9] .
C-circles are single-and double-stranded extrachromosomal DNA circles that, unlike other categories of extrachromosomal DNA species, are specific for the ALT pathway [10] . Potentially, C-circles represent the product of excision of over-elongated telomeres that have been previously amplified by homologous recombination between repeated telomeric sequences during ALT [3] . In the present study, we assessed for the presence of the ALT pathway, using the very sensitive and quantifiable C-circle assay, and other telomere markers in 63 grades II, III and IV gliomas. We next attempted to correlate these factors with clinical characteristics as well as with the occurrence of classical genetic/epigenetic markers.
Materials and methods

Ethics statement
Between 2007 and 2012, malignant glioma samples were obtained during therapeutic surgical management by the Neurosurgery Unit of Clermont-Ferrand hospital (France) and stored confidentially. These glioma samples were part of the "Tumorothèque Auvergne Gliomes" biobank (DC-2012-1584). This study obtained ethical approval from the ethics committees and the respective competent authorities. The authors state that they have complied with the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects.
Patients and tissue collection
The clinical samples used in this study were taken from the material resected during the course of a standard diagnostic and treatment procedure. Immediately after surgery, the samples were snap-frozen and stored in liquid nitrogen.
Each sample was analyzed under a light microscope after hematoxylin-eosin staining for assessing necrosis and tumor cell percentage. Samples with less than 50% of tumor cells were excluded from this study. Histological diagnosis and grading of gliomas were based on WHO criteria used at the time of sample analyses of the present study [11] . Four non-tumoral control brain samples (healthy controls, mean age of 27.3, standard deviation ± 2 years) were cadaveric specimens removed by autopsy 4-16 h following accidental death (Brain and Tissue Bank of Maryland). These four non-tumoral control samples, identified by the Brain and Tissue Bank of Maryland as corpus callosus (n = 1) and frontal cortex (n = 3), corresponded to white matter enriched in astrocytes and oligodendrocytes, tissue from which gliomas originate. Tumor and control samples were processed by cryogenic grinding used for homogenization in powder and equally distributed into at least three vials, as described previously [12] . For each sample, two vials were used for DNA and RNA extractions.
Survival was calculated from the date of surgery. The extent of tumor resection was evaluated essentially based on two criteria: the surgical procedure report by the neurosurgeon and the presence of a persistent contrastenhancement on the early post-surgery (48 h) CT scan or MRI. The degree of tumor resection was classified as: (i) gross total resection (GTR) when tumor surgery was optimal and no contrast enhancement detected at 24/48 h postsurgery MRI, or (ii) as partial resection (PR) when contrast enhancement was detected.
DNA sequencing for IDH1/2 mutational analysis and methylation status of MGMT promoter
Genomic DNA was isolated from frozen tissues using the QIAamp DNA Mini Kit (Qiagen) and stored at −80 °C. IDH1 and IDH2 genotyping and MGMT promoter methylation analyses were performed as previously described [12] [13] [14] and detailed in Supplementary methods.
Analysis of 1p/19q codeletion, INA and immunostaining
The analysis of 1p/19q codeletion, internexin neuronal intermediate filament protein alpha (INA) expression [15, 16] and immunostaining analyses were detailed in Supplementary methods.
Measurements of ALT-specific C-circles
The C-circle assay, which detects partially single-stranded telomeric (CCC TAA )n DNA circles (C-circles) amplified by the Phi29 polymerase in the absence of dCTP, was performed as described previously [10] and detailed in Supplementary methods.
Detection of ALT-associated promyelocytic leukemia nuclear bodies (APBs) at the telomeres
APBs detection was conducted according to protocols previously described [5, 17] and detailed in Supplementary methods.
Telomeric DNA quantification by dot blot
Ten nanogramms of genomic DNA were transferred to a nylon membrane (Hybond N+; GE Healthcare) in a dot blot apparatus (Bio-Rad). After high-stringency washes, the membrane was hybridized overnight, in Church buffer, with a 32 P-labeled telomeric repeat [TTA GGG ] 3 probe that had been end-labeled with 100 µCi 32 P-γATP at 37 °C for 40 min using T4 polynucleotide kinase. After detection, the membrane was stripped and re-probed with an Alu-specific [GTG ATC CGC CCG CCT CGG CCT CCC AAA GTG ] 32 P-labeled probe, as above.
Measurement of hTERT expression
Total RNA was isolated from tumors using RNeasy Mini Kits (Qiagen). A reverse transcription reaction was performed on 500 ng RNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems) according to manufacturer's instructions. hTERT expression was measured using the nanofluidic digital PCR array platform (Fluidigm technology). The expression level of hTERT for each sample was calculated compared to the three housekeeping genes TBP, RPL13A and PPIA, identified as valid control genes in human glioma [18] and using the ΔΔCt method [19] .
Measurement of telomeric DNA transcription (TERRA)
Two micrograms of tumor sample RNA were reverse transcribed using the Revertaid first strand cDNA synthesis kit from Thermo Scientific-Fermentas and quantified using specific primers as previously described [20] and detailed in Supplementary methods.
Cell lines and cell culturing
Cell lines and culturing are described in Supplementary methods.
Telomere length measurement of human cancer cell lines by telomere restriction fragment (TRF) analysis
Measurement of telomere length was performed by Southern blot analysis, also referred to as telomere restriction fragment (TRF) analysis as already described [21, 22] and detailed in Supplementary methods.
Statistical analysis
Statistical analysis was performed using the Stata software, version 12 (StataCorp, College Station, TX, USA). Tests were two-sided, with a type I error set at α= 0.05. Baseline characteristics were presented as mean ± standard deviation (sd) or as median [interquartile range] for each independent group for continuous data and as number of patients and associated percentages for categorical parameters. Comparisons of characteristics between groups were analyzed using Chi-squared or Fisher's exact test for categorical variables, and Student's t-test or Mann-Whitney test for quantitative variables when assumptions of t-test were not met [(i) normality verified by the Shapiro-Wilk test and (ii) homoscedasticity by the Fisher-Snedecor test]. Correlation between quantitative parameters was accessed using correlation coefficient noted r (Pearson or Spearman according to statistical distribution). Multivariate analysis was considered to take into account adjustment on possible confusing factors according to univariate analysis and literature: age, WHO grade, surgery resection. Overall survival (OS) was defined as the interval from surgery to death, regardless of the cause of death. OS curves and estimates were constructed using the Kaplan-Meier method. The log-rank test was used in a univariate analysis to test the prognostic value of patient characteristics. Cox proportional hazards regression was used to investigate prognostic factors in multivariate situation by backward and forward stepwise analysis of the factors considered significant in univariate analysis (entered into the model if p ≤ 0.15) and according to clinically relevant parameters. The proportional hazard hypotheses were verified using Schoenfeld's test and plotting residuals. The interactions between possible predictive factors were also tested. Results were expressed as hazard ratios (HR) and 95% confidence intervals (CI).
Results
A total of 63 malignant glioma samples were analyzed; patient characteristics are outlined in Supplementary  Table 1 . According to the previous WHO glioma classification [11] , this cohort comprised 23 GBM (mean age of 63.0 ± 9.5 years), 32 grade III (mean age of 57.4 ± 12.6 years) and 8 grade II (mean age of 40.1 ± 10.0 years). However, importantly, the definition of glioma sub-classes for our statistical analyses was based on criteria similar to those used in the new WHO classification [23] , meaning that, for instance, grades II and III were grouped together but further classified according to their IDH1/2 and 1p/19q codeletion status. All patients underwent surgery. Highgrade (III and IV) IDH WT glioma patients were treated by concurrent chemoradiation and adjuvant chemotherapy (temozolomide), while IDH-mutated glioma patients did not receive concurrent chemoradiation and were treated on a case-by-case basis with protocols selected by our neuro oncology staff (chemotherapy and/or radiation, not simultaneously).
Occurrence of the ALT mechanism of telomere maintenance
All 63 glioma samples were analyzed for the presence of ALT-specific C-circles (Fig. 1A, Supplementary Table 1) . We chose the so-called "C-circle assay" to measure ALT activity, a technique developed by Reddel and co-workers, because it is highly specific, highly sensitive and quantifiable and can work with as little as 30 ng of DNA [10] . The intensities of C-circle signal for cells from a telomerase positive cancer cell line, HeLa, as well as for a prototype of ALT positive cells, U2OS, an osteosarcoma-derived cell line, were measured under identical conditions. Two out of the 9 C-circle positive tumors had a higher signal than U2OS, both of which were IDH1/2 WT GBM (Supplementary Table 1 ). Since the C-circle method for identification of the ALT mechanism is recent, we set out to detect in parallel, on a subset of samples, the presence of ALTassociated promyelocytic leukemia nuclear bodies (APBs) (Fig. 1B) . In the C-circle positive tumors, co-localizing signals were detected in the microscope (Fig. 1B) , but not in the ALT negative tumors (data not shown).
Nine out of the 63 samples analyzed (14.2%) were positive in the C-circle assay. The IDH1/2 mutated and IDH1/2 WT groups exhibited a statistically significant difference, with only 3 C-circle positive tumors among the 49 IDH WT gliomas (p = 0.001; Table 1 ). Six out of the 9 (66.7%) C-circle positive tumors versus only 8/54 (14.8%) C-circle negative tumors were IDH-mutated, pointing out to a statistically significant association between IDH1/2 mutations and ALT (p = 0.001, Table 1 ). In addition, C-circle positive patients were diagnosed at a younger age than C-circle negative patients (p = 0.04, Table 2 ).
Median survival was statistically different between the patients negative (15.8 months) and positive (41.9 months) for C-circle, when considering the entire population (p = 0.03, HR = 0.28, 95% CI [0.09; 0.90]). In addition, 5-year survival was 22% in C-circle negative versus 62% in C-circle positive tumors. Moreover, even if one of the 6 C-circle positive living patients died, the difference would remain statistically significant. When using multivariate model adjusted on the diagnosis age, histopathology grading and surgery resection, there was a trend for a significantly different OS depending on C-circle status (p = 0.09, HR = 0.35, 95% CI [0.10; 1.17]). Therefore, C-circle status did not appear to be an independent prognostic factor in our series of 63 gliomas.
34/63 tumors (54%) exhibited methylation of MGMT exon 1. MGMT promoter methylation correlated not only with the occurrence of IDH1/2 mutations (p = 0.001) but also with the presence of C-circles (p = 0.02; Table 1 ). This relation was less robust when considering the IDH mutated and IDH WT groups separately, but a trend was observed in the IDH WT group (39.1 vs. 100%, p = 0.07). Therefore, MGMT methylation correlates with the presence of the ALT mechanism.
hTERT expression
The expression of hTERT, encoding the catalytic subunit of telomerase, exhibited a mean increase of 9.3-fold in the 43 tumors tested in comparison to four control brain samples (Table 1 ). Although hTERT expression was different between IDH mutated and IDH WT gliomas (5.0 ± 6.1 and 10.1 ± 7.6 respectively), this difference was not statistically significant (p = 0.12, Table 2 ), most likely due to the small number of IDH mutated samples (n = 14).
Overall survival was inversely correlated with hTERT expression in univariate (HR = 1. [24] , and even in the IDH WT group (36/49; HR = 1.09, [1.03-1.15] p = 0.002). Therefore, hTERT expression was an independent negative prognostic factor in the whole population. All 5 C-circle positive gliomas in which it was measured exhibited a very low, undetectable, rate of hTERT expression, whereas expression was higher in C-circle negative gliomas (10.5 ± 7.2, n = 38, p < 0.001; Table 1 ), highlighting the existence of a moderate inverse correlation between hTERT expression and the ALT mechanism (r = 0.31, p = 0.04). P-labeled (TTA GGG ) 3 telomeric probe. All 64 samples were processed similarly, but a few examples only are shown here for illustration. Absolute C-circle values were measured by quantifying the signal after subtraction of the background signal on the nitrocellulose membrane. The vertical bars below represent the respective intensities of these values. The horizontal dashed line, which represents the C-circle value measured for HeLa cells (which are telomerase-positive), was arbitrarily chosen to establish a cut-off value below which tumors were considered ALT negative. Genomic DNA from an osteosarcoma-derived cell line, U2OS, a prototype of ALT positive cells, was used as a positive control for the C-circle reaction. B Detection of APBs by immunofluorescence using combined Telo-FISH analysis (red) and labeling with anti-PML antibodies (green). This is an example of a grade B oligodendroglioma (tumor #76) that was found to be ALT positive using the C-circle assay, representative of four analyzed tumors that were C-circle positive, two primary GBM and two grade B oligodendrogliomas
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Telomeric DNA content and telomeric DNA transcripts (TERRA)
In the current study, we had approximately 100 ng of tumor DNA available for each sample and this was not enough if we wanted to measure telomere length using telomere restriction fragment (TRF) analysis. To increase the sensitivity, we quantified telomeric DNA (TTA GGG repeats) with respect to an internal control (amount of Alu repeats), referred to as the Telo/Alu dot blot method (see "Materials and methods"), which we performed here using 10 ng of tumor DNA per sample ( Fig. 2A; Supplementary Table 1 ; Supplementary results). Using six different human cell lines, we confirm that the Telo/Alu dot blot signals were proportional to telomere length measured by TRF (Fig. 2B and Supplementary results), and can be useful to approximate absolute values of telomere length, in kilobases.
No statistically significant difference in telomeric DNA content nor in TERRA expression [25, 26] was found in relation with IDH1/2 mutational status ( 
Analysis of classical molecular markers in a context other than telomeric
IDH1/2 mutation status
Within the IDH WT group (n = 49), overall survival was similar between GBM (n = 23) and grade III gliomas (n = 25), 1.03 and 1.32 year, respectively. Median survival 
ATRX inactivation
In ALT positive tumors, inactivation of the ATRX gene product by mutation, insertion or deletion causes a lack of nuclear expression detected by immunolabeling, while tumors without ALT show robust nuclear labeling for ATRX [27, 28] . An absence of ATRX protein expression was found in 5/59 tested gliomas. This absence of functional nuclear ATRX was linked to activation of the ALT pathway (p = 0.001, Table 1 ), but also to the presence of an IDH1/2 mutation (p < 0.001, Table 2 ), but not to MGMT promoter methylation (p = 0.15). Interestingly, ATRX was nuclear (and therefore presumably functional) in all 3 C-circle positive GBMs.
MGMT exon 1 methylation status
34 (54%) tumors had their MGMT promoter methylated (Supplementary Table 1 
P53 and Ki-67 immunostaining
P53 immunoreactivity was not correlated with any parameter, while the proliferation marker Ki-67 was found to be an independent prognostic factor. Indeed, a low Ki-67 immunostaining was associated with better survival (p < 0.001).
In addition, a low Ki-67 score is also associated with C-circle positivity (p = 0.02, Table 1; Supplementary Table 1) .
Discussion
In the present study, we have measured, in a small cohort of human malignant gliomas, basic telomeric parameters P-labeled Alu probe (bottom panel ) that was used to normalize the telomeric signal to the total amount of genomic DNA. All 64 samples were processed similarly, but a few examples only are shown here for illustration. B Telomere length was measured in six cell lines using TRF analysis (3 µg DNA per sample). Telomeric DNA content was measured in parallel in these six cell lines using the Telo/Alu method, as described above in A. This aimed at establishing a correlation between the total amount of telomeric DNA determined by the dot blot analysis and absolute telomere length measured in parallel using TRF analysis. A 32 P-labeled (TTA GGG ) 3 telomeric probe was used for both types of measurements. Horizontal dotted lines within the gel represent the upper and lower limits of each smear of telomeric tracts. The center of this smear is usually used to assess a telomeric mean value in kilobases of DNA. Note that the length of the smear is also important because it reflects the degree of scattering of all telomeres lengths around the mean value of the whole cell population and evaluated their potential association with classical tumor markers and clinical outcome. Some of our conclusions confirm previous studies [7, 29, 30] , while others represent novel findings, which will have to be confirmed on a larger cohort. We have described a simple dot blot technique which, coupled with telomere length measurement in cell lines for calibration, allows to evaluate telomeric DNA content and telomere length in these tumors using as little as 30 ng of DNA. In parallel, the already described C-circle technique, which accurately and specifically measures ALT activity, can also be used with similar low amounts of tumor DNA. There are currently three main methods for detecting ALT in tumors. The first one is TRF Southern-blot analysis of telomere length profile, also used here (Fig. 2) . In ALT cells, telomeres range from very short to extremely long in individual cells, with mean telomere length (>20 Kb) being about twice of that of cells with positive telomerase activity or normal somatic cells (5-10 Kb). Therefore, ALT cells have long and heterogeneous telomeres as compared to the shorter and more homogeneous telomeres of ALT negative cells. TRF analysis currently uses around 3-5 µg of DNA per sample. The second method is that of the C-circles, used here, in which only 30 ng of DNA are needed. The third method does not use tumor DNA as the starting material. It consists in the detection, in tumor sections, of ALT-associated PML bodies (APBs), which are promyelocytic leukemia (PML) bodies that contain telomeric DNA and telomere binding proteins. This method, also used here (Fig. 1B) , is labor-intensive, making screening of large numbers of tumors difficult. However, recently, a variation of this assay, in which telomere FISH was used to detect ultra-bright telomeric signals, was used to analyze more than 6000 tumor samples, mostly in tissue microarray format studies [31] .
An interesting finding of the present study was that all three ALT positive tumors detected among the 23 GBM were wild type for IDH1/2, while the remaining six ALT positive tumors detected among the 40 lower grades, were all mutated for IDH1/2. Importantly, GBM that were both C-circle/ALT positive and IDH1/2 WT did not exhibit loss of ATRX function, unlike ALT positive grade II and III gliomas which were all IDH1/2 mutated. This highlights the relevance to measure C-circles rather than ATRX protein expression to identify ALT positive tumors among IDH WT malignant gliomas. In addition, these observations lead to propose that ALT activity in GBM might not have the same causes and consequences as ALT activity in lower grades. Therefore, measuring ALT activity in all grades of gliomas will undoubtfully allow to distinguish sub-classes of gliomas. However, it should be stressed out again that larger numbers of analyzed cases will be needed in order to establish solid conclusions regarding the potential existence of two (or more) different sub-classes of ALT tumors.
Another new finding from the present study was that MGMT promoter methylation associated with the ALT pathway both in the IDH mutated and IDH WT groups. In fact, it has already been reported that MGMT promoter methylation associated with mutations in IDH1/2 [32, 33] as well as with increased survival [33] . Our data also reveal, in multivariate analysis, a highly significant correlation between OS and a low Ki-67 score (p = 0.004, HR = 1.05) as well as a trend to a correlation between OS and C-circle positivity (p = 0.09, HR = 0.35). Our conclusion that a low Ki-67 score is associated with C-circle positivity should be toned down by the fact that the Ki-67 value was unknown for 5/9 C-circle positive tumors, and therefore is based on a small number of cases.
As expected, there was a strong inverse correlation between hTERT expression and the presence of a functional ALT mechanism. In addition, high levels of hTERT expression correlated with decreased survival, especially in 1p/19q non-codeleted patients. This agrees with recent findings showing that the presence of mutations in the hTERT promoter of GBMs, associated with increased hTERT expression, correlated with decreased survival in 1p/19q non-codeleted patients [24] . We found a positive correlation between telomeric DNA content and the presence of C-circles, which was expected since ALT telomeres are much longer in average than telomerase-maintained telomeres [3] . However, we believe it would be relevant to detect the presence of high versus low telomeric DNA content by using just a simple technique (the Telo/Alu method) since telomere length might represent a marker of tumor radiosensitivity [34] . On the other hand, we found no positive correlation between high telomeric DNA content and the presence of an IDH1/2 mutation. This was not surprising since a substantial number of tumors were IDH1/2 mutated but ALT negative.
In summary, achievement of a molecular diagnostic of ALT activation using the C-circle assay provides several major advantages. First, this assay specifically, accurately and rapidly identifies ALT positive tumors using as little as few tens of nanograms of tumor DNA. This will be particularly useful for GBMs since those, contrary to low grade gliomas, can be wild type for both IDH1/2 and ATRX and yet develop the ALT pathway. Therefore, in these GBMs, routinely assessing IDH1/2 mutations by sequencing and ATRX expression on tumor sections would not represent the right assay to detect ALT. Moreover, the C-circle assay reflects the overall ALT activity of the tumor, DNA being extracted from the whole chirurgical sample, contrary to the detection of ALT-associated PML bodies or FISH techniques, which both might accidentally analyze only a subset of tumor cells. In addition, FISH only indirectly assesses ALT activity, which is deduced from the signal measuring the amount of telomeric sequences, which might be misleading given that some tumors might exhibit long telomeres but yet be ALT negative. New ALT targeting therapies are currently under development [35] and it is therefore urgent to develop a reliable clinical test such as the C-circle assay to measure ALT activity in glioma tumors.
